Introduction
We have recently reviewed the results of a standard 100-,ug test dose of luteinizing hormone/follice stimulating hormonereleasing hormone (LH/FSH-RH) in 155 patients with hypothalamic-pituitary-gonadal dysfunction a). Though 88% of these patients were clinically hypogonadal at the time of testing and had low endogenous gonadotrophin secretion an LH response or FSH response or both occurred in 90%. It was therefore hoped that repeated administration of the synthetic decapeptide would result in the induction of gonadotrophin synthesis, its release, and gonadal stimulation. We here report the results of such treatment.
Dose Regimen
Studies of the time course of action of the releasing hormone given by intramuscular, intravenous, and subcutaneous routes showed it to be equally effective in promoting increased circulating levels of LH and FSH by each route with a duration of action of between five and seven and three and 'five hours respectively (Mortimer et al., 1973 b) . It was therefore decided that when sufficient supplies of the material became available long-term therapy in patients with hypogonadotrophic hypogonadism would be initiated by repeated subcutaneous injections. A dose of 500 Fg was used since experience showed that patients with hypothalamic or pituitary disease would require a higher dose than normal subjects to produce an adequate response. Therapy was continued with this dose administered by the patients themselves subcutaneously into the anterior abdominal wall or thigh. Injections were repeated at eight-hour intervals in view of the known time course of gonadotrophin secretion. One patient, treated when the supply of the drug was unavoidably curtailed, received a more varied regimen and is considered separately. All patients were tested before treatment and at intervals during treatment with 100 and 500 Fg LH/FSH-RH, measurement of serum LH and FSH levels being carried out over a four-hour period. The duration of treatment varied from four weeks in the prepubertal patients to between 26 weeks and one year in the adults.
Patients
Twelve male patients with clinical hypogonadism and pituitary or hypothalamic disease were studied. PREPUBERTAL PATIENTS Craniopharyngioma.-Four patients aged 14 to 22 years had craniopharyngiomas. Three had had excision of the tumour followed by irradiation, while one had had irradiation only. These procedures had been performed between six months and 10 years, previously. All were receiving intramuscular growth hormone therapy. Three were also receiving thyroxine and three hydrocortisone replacement.
Isolated Growth Hormone Deficiency.-One patient, aged 20 years, had isolated growth hormone deficiency. He was also receiving intramuscular growth hormone.
None of these patients except one (craniopharyngioma) showed an LH or FSH response to clomiphene given in a dose of 3 mg/kg/daily for 10 days.
ADULT PATIENTS Isolated Gonadotrophin Deficiency.-Four patients aged 22 to 24 years had so-called isolated gonadotrophin deficiency. Previously we suggested that this syndrome probably represents a deficiency of LH/FSH-RH rather than a primary gonadotrophin deficiency (Marshall et al., 1972) . All had low or undetectable basal serum gonadotroDhin levzls which failed to respond to clomiphene. There was no evidence of a deficiency of other pituitary hormones. These patients had been treated previously with either intramuscular testosterone proprionate or human chorionic gonadotrophin (HCG) or both. One patient, previously impotent and azoospermic, had received intramuscular Pergonal (human menopausal urinary gonadotrophins; HMG) and had successfully fathered a child.
Craniopharyngioma.-One 33-year-old man had had a craniopharyngioma decompressed and irradiated 19 years previously and had also fathered a child after HMG therapy. He was unresponsive to clomiphene.
Acromegaly.-A 32-year-old man had received external pituitary irradiation for acromegaly one year before treatment and he was hypogonadal. Basal growth hormone levels were reduced from 17 to 4 ng/ml and the paradoxical rise during a glucose tolerance test was reduced from 55 to 19 ng/ml. His acromegaly clinically improved. He had low 17 (3-hydroxyandrogen (17-OHA) levels and greatly impaired potency.
Hypothalamic Tumour.-One patient, aged 37 years, had a diffuse hypothalamic tumour of unknown origin which went into remission after high-dose dexamethasone therapy and hypothalamic irradiation. At the time of the study he was maintained on hydrocortisone, thyroxine, and DDAVP (Edwards et al., 1973) as replacement therapy. He was unresponsive to clomiphene.
All these patients had been off any form of gonadal steroids or gonadotrophin therapy for at least four months before the study began and were clinically hypogonadal, with loss of potency and body hair and small genitalia. All the patients had azoospermia in the first ejaculate produced during treatment except for the man with the craniopharyngioma, who had a total count of 600,000 dead spermatozoa, presumably lying in situ from HCG therapy terminated four months earlier.
Assays Serum LH and FSH levels were measured by specific radioimmunoassays as described previously and the results expressed in mU/ml of M.R.C. standard 68/40 for LH and 68/39 for FSH, the contents of each ampoule being taken as 39-8 and 32 units respectively. Normal adult male basal levels of LH and FSH range from less than 0 4 to 6 mU/ml and from less than 0-2 to 5 9 mU/ml respectively. Plasma 17-OHA levels were estimated by the method of Anderson (1970) . This measures predom tly testosterone and dihydrotestosterone. (Normal male range at 9 a.m. for plasma 17-OHA 5-0-22-5 ng/ml.) Plasma sex-hormone-binding globulin (SHBG) was measured by the method of Rosner (1972) and the results were expressed in 10-8 mol of dihydrotestosterone bound per litre. The normal adult male range is 2-10 to 5-1 x 10-8 mol/l. Higher levels are characteristically seen in prepubertal subjects (August et al., 1969; Forest and Bertrand, 1972) .
Non-protein-bound ("free") androgen levels were estimated by calculating the ratio of total 17-OHA to SHBG. When expressed as a percentage the normal adult male range is 1-42% to 2.0%.
Plasma oestradiol was measured by radioimmunoassay (Hotchkiss et al., 1971) . The normal adult male range is from less than 10 to 50 pg/ml. All blood samples were separated immediately and stored at -20°C until assayed.
Gonadotrophin Responses PREPUBERTAL PATIENTS
Craniopharyngioma.-Of the four patients with craniopharyngiomas two had undetectable serum LH levels and two had levels of 0 7 mU/ml before treatment; however, all had detectable circulating FSH (between 0 3 and 1-0 mU/ml). The responses during the initiation of therapy in one of these patients is shown in fig. 1 . Three patients failed to show a response in LH to an intravenous test dose of 100 jig of the releasing hormone before treatment though a small but significant rise in FSH was seen in each case. When the first subcutaneous dose of 500 Lg was given all three patients showed a rise in both LH and FSH. In the fourth patient, with detectable LH and FSH basally, there was no further response to 100 1Lg of the releasing hormone but a simultaneous increase in both gonadotrophins occurred when 500 ,ug was injected. This patient was the only one who had shown a response to clomiphene. As treatment with 500 Fg was started and continued there were progressive increases in both gonadotrophins in all four patients, with LH secretion becoming equal to or exceeding that of the FSH response. Thus though initially there was a larger FSH than LH response before treatment was started, by the end of four weeks the response of LH was greater than that of FSH. Therapy was discontinued after four weeks in three patients as it was felt unwise to induce puberty while they were still receiving growth hormone therapy. In five patients (two prepubertal boys with craniopharyngiomas, the man with the craniopharyngioma, the man with the diffuse hypothalamic tumour, and one of the men with isolated gonadotrophin deficiency) the standard 100-,ug LH/FSH-RH test was repeated after four to six weeks of therapy after being off treatment for one to seven days. Before treatment in these patients the response of FSH was much greater than that of LH, whereas after treatment the secretion of LH was greater than that of FSH. The levels of both LH and FSH were higher after treatment than before ( fig. 3) 
Induction of Androgen Secretion and Puberty in Prepubertal Patients
Of the five prepubertal patients three were still growing on intramuscular growth hormone therapy. Gondadotrophinreleasing hormone therapy was discontinued after four weeks in these subjects since it was considered undesirable to induce puberty while they still had growth potential. All had shown a rise in gonadotrophin and 17-OHA levels during that time. The remaining two patients, aged 19 and 22 years, were also on growth hormone therapy but since their growth was slowing down it was decided to attempt to induce puberty in the hope that there would be potentiation of growth as in normal puberty. Before treatment one patient had pre-adolescent genitalia with vellus over the pubes indistinguishable from that of the abdominal wall-that is, stage 1 (Tanner, 1958) . After eight weeks of treatment this patient showed an increase in spontaneous erections and stage 2 pubic hair development. The other patient before treatment had slight pubertal enlargement of the testes and scrotum with sparse growth of pigmented downy hair at the base of the penis (stage 3). After nine weeks of treatment there was an increase in testicular volume of from 6 to 12 ml on the right and from 4 to 8 ml on the left. Spontaneous erections became frequent and there was an increase in coarse pubic hair. Gonadotrophin secretion continued within the normal basal adult male range in these subjects while treatment was maintained though the 17-OHA levels increased only slightly, from pretreatment levels of 0 4 to 1-7 ng/ml to between 1-4 and 2-4 ng/ml-that is, below the normal adult range. Plasma oestradiol levels did not change and were within the normal adult male range. Plasma SHBG was above the adult range before treatment in four patients (between 7-7 and 22-6 x 10-8 mol/l.), as is usually seen before puberty (August et al., 1969; Forest and Bertrand, 1972) ; in the other patient it was normal (4-6 x 10-8 mol/l.). In the three patients treated for four weeks only there was no consistent change in SHBG. In the two treated for longer the SHBG levels fell. In these patients changes in circulating levels of free androgens inferred from the ratio of total 17-OHA to SHBG and expressed as a percentage rose from between 0-02% and 0-18% basally to between 0 03% and 0-32% after treatment but were still below the normal adult male range.
Induction of Androgen Secretion and Potency in Adult Patients
All seven adult patients studied had an increase in potency within seven to 14 days of beginning treatment. Before treatment 17-OHA levels reached between 1 0 and 3-1 ng/ml. In every case there was an increase in 17-OHA levels though only two patients showed a rise to within the normal range on more than two occasions. These two subjects achieved maximum levels of 15-5 and 7-5 ng/ml after two and four weeks of treatment respectively but values then fell and were maintained between 3-1 and 4-8 ng/ml. In the remaining five patients, though levels were subnormal (between 0 4 and 4-8 ng/ml) improved potency was well maintained. Three patients had normal potency. Plasma 17 3-oestradiol levels remained within the normal range throughout treatment except in three patients on three isolated occasions, when raised levels of 55, 98, and 171 pg/ml were recorded. SHBG levels were above normal before treatment in one patient (5-8 x 10-8 mol/l.), low in two patients (1-4 and 1-5 x 10-8 mol/l.), and normal in the other four (2-7 to 5 0 x 10-8 mol/l. The fourth patient in whom spermatogenesis was induced was the man with acromegaly ( fig. 6 ). Initial investigations showed that he had a basal 17-OHA level of only 1-7 ng/ml.On treatment this rose to a maximum of 5-2 ng/ml at six weeks and was then maintained at between 3-8 and 4-5 ng/ml. When seen initially he had a much reduced potency but was able to produce a specimen for seminal analysis, which contained no spermatozoa. During treatment, however, he showed a progressive rise in total sperm counts from 50,000 to 13-6 x 106 at 25 weeks and 60-8 x 106 at 48 weeks with a motility of 40%. Before treatment he had a basal LH level of 3-8 mU/ml but raised FSH level of 17-3 mU/ml. Initially the FSH values after a 500-,ug dose of LH/FSH-RH were greater than 50 mU/ml, but these gradually fell to 1-6 mU/ml during therapy as the sperm count rose. The LH values in contrast fluctuated between 6 and 15 mU/ml without showing a well-defined pattern of response. TESTICULAR VOLUME In all seven adult patients there was a clear increase in testicular volume-from between 1 and 3 ml before treatment to between 6 and 12 ml after 12 to 35 weeks-together with an increase in the size of the penis. Beard growth and body hair improved i three patients.
Effect of Clomiphene and LH/FSH-RH Dose Variation
The adult patients with the craniopharyngioma and the diffuse hypothalamic tumour were both unresponsive to clomiphene before LH/FSH-RH therapy. At nine and six weeks respectively LH/FSH-RH was stopped and clomiphene was given in a dose of 3 mg/kg/day. In both cases LH and FSH levels became undectable, 17-OHA levels fell, and the patients became impotent again. Resumption of treatment with LH/FSH-RH at a dose of 100 jg 8-hourly produced only a small increase in 17-OHA and a negligible effect on potency. When full dosage was given again gonadotrophin and androgen secretion and normal potency returned within 10 to 21 days in both patients (fig. 5 It is also evident that if therapy is maintained potency will return in the adult patients. Surprisingly, however, in six of the seven adult patients there was an early increase in potency, seven to 14 days after starting therapy, which was maintained despite circulating 17-OHA levels well below the lower limit of the normal male range. At these levels most other patients seen are impotent. The unusual degree of potency recorded by these subjects is not explained on the basis of normal free androgen levels in the presence of low total androgens, since levels of the binding protein SHBG were either normal or high in five of them and their free testosterone levels were well below the normal adult male range. In only one patient did low basal free androgen levels rise to the normal range during therapy and remain there. He also had low SHBG levels. Plasma oestradiol levels were also within the normal male range except on rare occasions. The rapid return of potency in these patients may therefore have been due to factors other than those which are simply androgen-mediated. Of relevance to these observations may be the findings of Moss and McCann (1973) and Pfaff (1973) , who noted a marked increase in the number of lordotic responses in ovariectomized and hypophysectomized rats after subcutaneous treatment with the synthetic decapeptide. These workers suggested that LH/FSH-RH may have a direct promoting action on sexual behaviour in rats indepedent of its hormone effects, and this may also be the case in man.
Apart from the return of potency, spermatogenesis was induced in four patients. Total sperm counts increased from zero (or 600,000 dead spermatozoa in one patient) to maximum values of 7-8, 36&7, 60-8, and 432 x 106 in these patients. The patient with acromegaly was particularly interesting. Before treatment he had low 17-OHA levels with LH levels in the normal range together with azoospermia despite raised FSH levels. The LH response to a standard 100-klg test dose of LH/FSH-RH was normal but the FSH response was excessive. A similar pattem of response in patients with oligospermia or azoospermia has been noted previously (Mortimer et al., 1973 a) . As treatment continued, however, spermatogenesis was induced, presumably as a result of the production of intratesticular androgens in the presence of FSH, and the maximum FSH values after administration of the releasing hormone began to fall as the sperm count began to rise. This pattem of response though less marked also occurred in the other patients in whom spermatogenesis was induced. This suggests that the factor produced during spermatogenesis, often called "inhibin," was being released into the circulation and was exerting a negative feedback effect on FSH secretion. It seems, therefore, that the site of action of inhibin was primarily at the pituitary level since circulating LH/FSH-RH levels were being maintained by repeated subcutaneous injections. It is also evident that pituitary responsiveness in male subjects may be modified by circulating substances other than testosterone or oestrogen.
In conclusion, therefore, we suggest that long-term treatment with LH/FSH-RH 500 tug eight-hourly self-administered by subcutaneous injection may provide an efficient means of treating patients with hypogonadotrophic hypogonadism due to diseases of the hypothalamus or pituitary and may result in the return of potency and fertility. This treatment may replace the more expensive conventional therapy with natural human gonadotrophins. The promotion of potency out of proportion to the increase in circulating androgens suggests that its place in the treatment of psychogenic impotence should be explored, and these studies are under way. Lower doses have been found to be ineffective in these patients.
